University of Groningen
Tumor immunology in ovarian cancer
Merkus-Brunekreeft, Kim
DOI:
10.33612/diss.147014180
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Merkus-Brunekreeft, K. (2020). Tumor immunology in ovarian cancer. University of Groningen.
https://doi.org/10.33612/diss.147014180
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Kim L. Brunekreeft
TUMOR
IMMUNOLOGY
IN OVARIAN
CANCER
COLOPHON
Kim Liu-Yun Brunekreeft
PhD dissertation, University of Groningen, The Netherlands Layout: Floris Sprong
Cover design: ninamaakt.nl Photography: Dirk Jansen
Printing: Gildeprint - www.gildeprint.nl
Copyright © 2020 by Kim Liu-Yun Brunekreeft. All rights reserved. Any unauthorized reprint or use of this material is prohibited. No part of this thesis may be reproduced, stored or transmitted in any form or by any means without written permission of the author, or, when appropriate, of the publishers of the publications.
The studies in this thesis were performed at the department of Obstetrics and Gynecology of the University Medical Center Groningen (UMCG); the department of Molecular Internal Medicine, Medical Clinic and Polyclinic II, University Clinic of Würzburg, Würzburg, Germany; and the department of Developmental Immunology of the La Jolla Institute for Immunology, La Jolla, CA, USA.
This work was financially supported by the Junior Scientific Masterclass Groningen of the University of Groningen and the department of Obstetrics and Gynecology of the University Medical Center Groningen. The UEF-JSM Talent Grant (2014) and Jan Kornelis de Cock grant (2015) to drs. K.L. Brunekreeft. The Alexander von Humboldt Foundation and Bas Mulder Award to dr. M. de Bruyn (UMCG 2014-6719). Grants from the Netherlands Organization for Scientific Research (NOW) and Dutch Cancer Society (KWF) to prof. dr. E. Bremer.
Printing of this thesis was financially supported by the University of Groningen and the Graduate School of Medical Sciences of the the University Medical Center Groningen.
TUMOR IMMUNOLOGY
IN OVARIAN CANCER
Proefschrift
ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op woensdag 16 december 2020 om 16:15 uur
door
Kim Liu-Yun Brunekreeft
geboren op 25 januari 1990 te Taipei, Taiwan ROC The digital version of this thesis can be found online at:
https://www.gildeprint.nl/case/tumor-immunology-in-ovarian-cancer/ Or by scanning the QR-code.
Promotor Prof. dr. H.W. Nijman Copromotor Dr. M. de Bruyn Beoordelingscommissie Prof. dr. W. Helfrich Prof. dr. S. de Jong Prof. dr. H. Wajant Paranimfen K. Zunderdorp W. Foppen
TABLE OF CONTENTS
Chapter 1 Chapter 2 Chapter 3 Chapter 4 Chapter 5 Chapter 6General introduction, aim and outline of this thesis Deep immune profiling of ovarian tumors, draining lymph nodes and circulating cells during neoadjuvant chemotherapy.
OncoImmunology (2020) 9(1):1-12*
CD103+ intraepithelial T cells in high-grade serous
ovarian cancer are phenotypically diverse TCRαβ+
CD8αβ+ T cells that can be targeted for cancer
immunotherapy.
Oncotarget (2016) 15;7(46):75130-75144
Minimal MHC-I expression after neoadjuvant chemotherapy in ovarian cancer is negatively associated with T-cell-dependent outcome.
OncoImmunology (2020) 9(1):1-12*
Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death.
Molecular Cancer (2014) 13(1):85
Immune-humanized mice carrying patient-derived xenografts as neo-antigen discovery platform for ovarian cancer. Manuscript in preparation 11 23 63 101 119 149
*Published as: Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome. Oncoimmunology (2020) 9(1):1-12.
Summary, discussion, conclusion and future perspectives
Nederlandse samenvatting (Dutch summary) 1. Abbreviations
2. List of contributing authors 3. List of publications
4. Dankwoord (acknowledgements) 5. Over de auteur (about the author)
Chapter 7 Chapter 8 Appendices 175 187 196 200 203 204 210
